Taken together, these findings support the hypothesis that GLP-1-based therapies could modulate key inflammatory and immune mechanisms underlying inflammation-associated cancers (e.g., CRC and PDAC), potentially reducing progression or improving responsiveness to existing treatments [38]. This evidence concerns the gene GLP1R and colorectal carcinoma.